Sanofi India Q3 PAT seen up 8.4% to Rs 92.5 cr: Centrum

Net Sales are expected to increase by 6.1 percent Q-o-Q (up 10.1 percent Y-o-Y) to Rs 645 crore, according to Centrum.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney master your money IThe Winning Leap SME Special
Moneycontrol

Home » News » Earnings » Brokerage Results Estimates

Oct 19, 2016, 03.59 PM | Source: Moneycontrol.com

Sanofi India Q3 PAT seen up 8.4% to Rs 92.5 cr: Centrum

Net Sales are expected to increase by 6.1 percent Q-o-Q (up 10.1 percent Y-o-Y) to Rs 645 crore, according to Centrum.

Like this story, share it with millions of investors on M3

Sanofi India Q3 PAT seen up 8.4% to Rs 92.5 cr: Centrum

Net Sales are expected to increase by 6.1 percent Q-o-Q (up 10.1 percent Y-o-Y) to Rs 645 crore, according to Centrum.

Post Your Comments

Share Cancel

Centrum Broking (more)

, Centrum Broking |

Centrum has come out with its second quarter (July-September) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Sanofi India  to report net profit at Rs 92.5 crore, up 8.4 percent quarter-on-quarter.

Net Sales are expected to increase by 6.1 percent Q-o-Q (up 10.1 percent Y-o-Y) to Rs 645 crore, according to Centrum.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 9.1 percent Q-o-Q (up 12.1 percent Y-o-Y) to Rs 159 crore.

Centrum's report on Sanofi India

For Q3CY16, we expect Sanofi India (SIL) to report sales growth of 10% YoY and 6% QoQ to Rs6.45bn due to good growth in its flagship brands, namely, Lantus, Combiflam, Allegra, Clexane, Enterogermina, Amaryl M, Avil and Pentaxim which have reported strong growth.

Among major brands, Lantus, Cardace, Soframycin, Avil, Clexane, Frisium and Amaryl are under price control. SIL’s net profit is likely to grow 28% YoY to Rs925mn from Rs725mn due to good revenue growth and margin improvement. We expect tax rate to decline to 36.0% from 40.7%. SIL is among our top pharma picks.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click here

Buy, Hold, Sell ? Hear it first on M3
Sanofi India Q3 PAT seen up 8.4% to Rs 92.5 cr: Centrum

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login